研究組長介紹
沈蕾
電話：63846590-776365
郵箱：[email protected]
個人簡歷
1990- 1995 南京醫(yī)科大學 臨床醫(yī)學學士
1995- 2000 南京醫(yī)科大學 醫(yī)學博士
2001-2005 美國貝勒醫(yī)學院 博士后
2006-2011 美國斯坦福大學 助理研究員, 助理研究教授
2012.09-至今 上海交通大學醫(yī)學院上海市免疫學研究所 課題組長(PI),，研究員,，博士生導師
研究方向
脂肪組織代謝穩(wěn)態(tài)的免疫調控；天然淋巴細胞發(fā)育及功能的調控機制及其與炎癥性疾病的關系,。
科研項目
2020-2025：科技部國家重點研發(fā)計劃“蛋白質機器與生命過程調控”重點專項,，參與人，腸道重要致病菌感染與宿主關鍵因子互作促進結直腸癌發(fā)生發(fā)展中的蛋白質機器研究,，項目編號： 2020YFA0509200
2020-2023: 國家自然科學基金面上項目,，負責人，肝激酶B1(LKB1)調控脂肪2型天然淋巴細胞(ILC2)的功能影響肥胖及2型糖尿病發(fā)生,，項目編號#81971487
2020-2023: 上海市自然科學基金項目,，負責人，SUMO特異性蛋白酶1(SENP1)調控B細胞生發(fā)中心反應和抗體類別轉換的作用及機制,，項目編號：20ZR1430200
2020-2022: 上海市“科技創(chuàng)新行動計劃”科學儀器領域項目,，負責人，FACSymphony高參數(shù)流式分析儀用于全景式免疫監(jiān)測的開發(fā)和應用研究,，項目編號：20142202300
2020-2022：碧迪醫(yī)療器械（上海）橫向課題,，負責人，應用scRNAseq和high-parameter flow cytometry解析結腸癌腫瘤微環(huán)境中固有淋巴細胞的免疫應答特征，項目編號：2020HX009
2016-2019: 國家自然科學基金面上項目,，負責人,，SUMO特異性蛋白酶1 對脂肪組織巨噬細胞的調控作用以及與2型糖尿病發(fā)生的關系，項目編號：#81571533
2016-2019: 國家自然科學基金面上項目,，負責人,，PLZF對3型天然淋巴細胞(ILC3)發(fā)育和功能的調控作用及機制研究，項目編號：#31570921
2016-2018：國自然重大研究計劃,，參與者,，Dermo+ 間質細胞在腸道免疫反應中的作用機制，項目編號：# 91542120
2014-2017:國家自然科學基金面上項目,，負責人,，B淋巴細胞調節(jié)肥胖誘導胰島素抵抗的作用機制，項目編號：#81373210
2014-2017:國家海外高層次人才計劃,，負責人,，適應性免疫應答與2型糖尿病
2013-2015: 上海浦江人才計劃，負責人,，B細胞亞群在胰島素抵抗中的作用機制,，項目編號：#13PJ1405400
論文與專著
1. Wang L, Zhang H, Sun L, Gao W, Xiong Y, Ma A, Liu X, Shen L*, Li Q, Yang H. Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury. J Nanobiotechnology. 2020 Feb 26;18(1):38.
2. Ji Z, Wu S, Xu Y, Qi J, Su X, Shen L*. Obesity promotes EAE through IL-6 and CCL-2-mediated T cells infiltration. Front Immunol. 2019 Aug 27;10:1881.
3. Wang H, Shen L, Sun X, Liu F, Feng W, Jiang C, Chu X, Ye X, Jiang C, Wang Y, Zhang P, Zang M, Zhu D, Bi Y. Adipose group 1 innate lymphoid cells promote adipose tissue fibrosis and diabetes in obesity. Nat Commun. 2019, 10(1):3254
4. Cai T, Qiu J, Ji Y, Li W, Ding Z, Suo C, Chang J, Wang J, He R, Qian Y, Guo X, Zhou L, Sheng H, Shen L*, Qiu J*. IL-17-producing ST2+ group 2 innate lymphoid cells play a pathogenic role in lung inflammation. J Allergy Clin Immunol 2019 Jan; 143(1):229-244
5. Yu T, Zuo Y, Cai R, Huang X, Wu S, Zhang C, Chin YE, Li D, Zhang Z, Xia N, Wang Q, Shen H, Yao X, Zhang ZY, Xue S, Shen L*, Cheng J*. SENP1 regulates IFN-g-STAT1 signaling through STAT3-SOCS3 negative feedback loop. J Mol Cell Biol. 2017 Apr;9(2):144-153
6. McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest 2017 Jan 2; 127(1): 5-13
7. Shen L, Chng MH, Alonso MN, Yuan R, Winer DA, Engleman EG. B-1a Lymphocytes Attenuate Insulin Resistance.Diabetes. 2015 Feb; 64(2):593-603
8. Shen L, Zhang H, Caimol M, Benike CJ, Chakravarty EF, Strober S, Engleman EG. Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production. Eur J Immunol. 2015 Feb; 45(2):612-623.
9. McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Zhang H, Hui Yen Chng M, Engleman E.T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans.Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2637-43.
10. Winer DA, Winer S, Chng MH, Shen L, Engleman EG. B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance.Cell Mol Life Sci. 2014 Mar;71(6):1033-43.
11. (Co-first author) Winer D* Winer S*, Shen L*, Wadia P, Yantha J, Paltser G, Tsui H, Wu P, Davidson M, Alonso M, Leong H, Glassford A, Caimol M, Tedder T, McLaughlin T, Miklos D, Dosch HM, Engleman EG. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nature Medicine. 2011, May; 17(5):610-7
12. Zhang B, Lo C, Shen L, Sood R, Jones C, Cusmano-Ozog K, Park-Snyder S, Wong W, Jeng M, Cowan T, Engleman EG, Zehnder J. The role of Vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood. 2011 Apr 28;117(17):4569-79
13. Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY. A20 is an antigen presentation attenuator and its inhibition overcomes regulatory T cell-mediated suppression. Nature Medicine. 2008; 14(3):258-65
14. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nature Biotechnology. 2004; 22:1546-1553
15. Shen L, Schroers R, Hammer J, Huang XF, Chen SY. Identification of a MHC class II-restricted epitope in Carcinoembryonic antigen (CEA). Cancer Immunology and Immunotherapy. 2004; 53(5):391-403
16. Schroers R, Shen L*, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY. Human telomerase reverse transcriptase-specific T helper responses induced by promiscuous MHC Class II-restricted Epitopes. Clinical Cancer Research. 2003; 9(13): 4743-4755
17. Schroers R, Shen L*, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY. Identification of MHC class II-restricted epitopes in prostate-specific membrane antigen (PSMA). Clinical Cancer Research. 2003; 9(9):3260-3271
專利與技術許可
Modulation of cytokine signaling regulators and applications for immunotherapy. (2006). Inventors: Lei Shen and Si-Yi Chen. Licensing to ImmunoVac on April, 2007. US Serial # 11/165091; US Patent Application# 20060269519; European Patent # EP1781338.
榮譽與獎勵
國家海外青年高層次人才 上海市浦江人才
團隊介紹
本課題組圍繞代謝與免疫兩大系統(tǒng)在生理和病理狀態(tài)下相互作用的調控網(wǎng)絡進行研究, 在整體水平，聚焦免疫細胞尤其淋巴細胞對系統(tǒng)性代謝疾病如2型糖尿病的調控作用及臨床意義; 在細胞水平,，研究代謝因素以及胞內代謝通路對免疫細胞功能的影響和機理,。主要研究方向為：
1、探究肥胖誘導的胰島素抵抗免疫機制
2,、天然淋巴細胞ILC發(fā)育和功能的代謝調控機制
